Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer
18 nov. 2022 08h05 HE
|
Palisade Bio, Inc.
Established academic and corporate executive with proven track record leading large, multinational organizations across the pharmaceutical and medical device industries Well-versed with LB1148 -...
Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video
17 nov. 2022 08h30 HE
|
Palisade Bio, Inc.
Video illustrates the potential of LB1148 to reduce the formation of adhesions in gastrointestinal (GI) tissues and accelerate the time to the return of normal GI function Carlsbad, CA, Nov. 17,...
Palisade Bio Announces Reverse Stock Split
15 nov. 2022 11h15 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
14 nov. 2022 08h45 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc., (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio Announces Executive Leadership Transition
11 oct. 2022 09h25 HE
|
Palisade Bio, Inc.
Board Appoints JD Finley to Interim Chief Executive Officer Carlsbad, CA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company...
Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022
29 sept. 2022 08h35 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 sept. 2022 16h30 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...